Tirzepatide, a novel pharmaceutical agent, has emerged as a groundbreaking discovery in the terzipetide supplier realm of GLP-1 receptor agonism. Unlike previous GLP-1 receptor agonists, tirzepatide exerts its effects by simultaneously activating both the GLP-1 and GIP receptors. This dual mechanism of action contributes to a pronounced reduction i